BridgeBio Cash from 2010 to 2024

BBIO Stock  USD 27.05  0.07  0.26%   
BridgeBio Pharma Cash yearly trend continues to be very stable with very little volatility. Cash is likely to grow to about 376.3 M this year. Cash is the total amount of money in the form of currency that BridgeBio Pharma has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
2018-12-31
Previous Quarter
375.9 M
Current Value
475.4 M
Quarterly Volatility
110.2 M
 
Covid
Check BridgeBio Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BridgeBio Pharma's main balance sheet or income statement drivers, such as Interest Income of 18.9 M, Depreciation And Amortization of 6.2 M or Interest Expense of 85.4 M, as well as many indicators such as Price To Sales Ratio of 742, Dividend Yield of 4.0E-4 or Days Sales Outstanding of 92.54. BridgeBio financial statements analysis is a perfect complement when working with BridgeBio Pharma Valuation or Volatility modules.
  
Check out the analysis of BridgeBio Pharma Correlation against competitors.
To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.

Latest BridgeBio Pharma's Cash Growth Pattern

Below is the plot of the Cash of BridgeBio Pharma over the last few years. Cash refers to the most liquid asset of BridgeBio Pharma, which is listed under current asset account on BridgeBio Pharma balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from BridgeBio Pharma customers. The amounts must be unrestricted with restricted cash listed in a different BridgeBio Pharma account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. BridgeBio Pharma's Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BridgeBio Pharma's overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

BridgeBio Cash Regression Statistics

Arithmetic Mean227,636,611
Geometric Mean178,755,356
Coefficient Of Variation66.37
Mean Deviation144,684,386
Median91,995,000
Standard Deviation151,083,760
Sample Variance22826.3T
Range344.1M
R-Value0.85
Mean Square Error6982.5T
R-Squared0.72
Significance0.00007
Slope28,585,451
Total Sum of Squares319568.2T

BridgeBio Cash History

2024376.3 M
2023375.9 M
2022376.7 M
2021393.8 M
2020356.1 M
2019363.8 M
2018436.1 M

Other Fundumenentals of BridgeBio Pharma

BridgeBio Pharma Cash component correlations

About BridgeBio Pharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include BridgeBio Pharma income statement, its balance sheet, and the statement of cash flows. BridgeBio Pharma investors use historical funamental indicators, such as BridgeBio Pharma's Cash, to determine how well the company is positioned to perform in the future. Although BridgeBio Pharma investors may use each financial statement separately, they are all related. The changes in BridgeBio Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BridgeBio Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on BridgeBio Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in BridgeBio Pharma. Please read more on our technical analysis and fundamental analysis pages.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Information and Resources on Investing in BridgeBio Stock

When determining whether BridgeBio Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BridgeBio Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bridgebio Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bridgebio Pharma Stock:
Check out the analysis of BridgeBio Pharma Correlation against competitors.
To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.23)
Revenue Per Share
1.291
Quarterly Revenue Growth
114.619
Return On Assets
(0.40)
Return On Equity
(17.90)
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.